Aim: The study aims to compare the quality of life (QoL) outcomes in patients with psychodermatological disorders undergoing imaging-guided versus conventional treatments, focusing on QoL improvement, treatment adherence, and adverse events. Material and Methods: This comparative study included 120 patients aged 18–65 years with moderate psychodermatological disorders, including psoriasis, eczema, and acne. Participants were randomized into imaging-guided (n=60) and conventional treatment (n=60) groups. Imaging-guided interventions incorporated advanced techniques such as dermoscopy and ultrasonography, while conventional treatments involved standard topical and systemic therapies. QoL was assessed at baseline, three months, and six months using validated tools, including the Dermatology Life Quality Index (DLQI) and the Short Form Health Survey (SF-36). Treatment adherence and adverse events were recorded. Statistical analysis was performed to compare outcomes between the two groups. Results: The imaging-guided group demonstrated significantly greater improvements in QoL, with a reduction in mean DLQI scores from 12.8 ± 2.5 to 5.4 ± 1.7, compared to 12.6 ± 2.4 to 7.3 ± 2.0 in the conventional group (p < 0.001). Similarly, SF-36 scores increased from 45.6 ± 8.9 to 61.3 ± 10.2 in the imaging-guided group versus 44.9 ± 9.1 to 55.2 ± 10.5 in the conventional group (p < 0.001). Adherence rates were higher in the imaging-guided group (92.67%) than in the conventional group (84.33%; p < 0.05). Adverse events, including psychological distress, were less frequent in the imaging-guided group (5.00% vs. 10.00%; p = 0.038). Conclusion: Imaging-guided treatments significantly improve QoL, enhance adherence, and reduce adverse events compared to conventional therapies in patients with psychodermatological disorders. These findings support the integration of imaging technologies into standard care to achieve holistic and effective management.